Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Q4 2024 Management View CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA ...

Marion McCourt; Executive Vice President - Commercial; Regeneron Pharmaceuticals Inc. Christopher Fenimore; Chief Financial Officer, Senior Vice President - Finance; Regeneron Pha ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up ...

Reports Q4 revenue $3.79B, consensus $3.75B. “Regeneron’s (REGN) financial and commercial strength allows for continued investment in our ...

Eylea HD is poised to become the new standard-of-care for patients with wet age-related macular degeneration and diabetic eye diseases,” CEO Leonard Schleifer said on a call with investors early ...

Regeneron's CEO, Leonard Schleifer, once criticized arbitrary drug price increases by pharmaceutical companies. But in July, the company's eczema drug price increased by 3%. Regeneron said Sanofi ...